Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JAB-BX467
- Development stage
- Preclinical
- Lead developer
- Jacobio Pharmaceuticals Co., Ltd.
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JAB-BX467 is an immune-stimulating antibody-drug conjugate (iADC) developed by Jacobio Pharmaceuticals. It is designed to treat HER2-expressing solid tumors by combining a human epidermal growth factor receptor 2 (HER2)-targeting antibody with a small-molecule stimulator of interferon genes (STING) agonist payload. The drug's mechanism of action involves the targeted delivery of the STING agonist to the tumor microenvironment, where it activates the innate immune system, converting immunologically "cold" tumors into "hot" tumors. This approach is intended to address the high percentage of patients who do not respond to standard PD-1/PD-L1 checkpoint inhibitors. Preclinical studies have demonstrated that JAB-BX467 is stable, induces significantly less IL-6 compared to competitors, and can persistently eradicate tumor growth while establishing a strong immune memory effect. The candidate is currently in the IND-enabling stage, with an IND filing anticipated in the second half of 2026.
- Other names
- HER2-STING-iADCHER-2-STING-iADCHER 2-STING-iADC
02
Targets
STING (Stimulator of interferon genes protein)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on JAB-BX467.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JAB-BX467.